Inclusion Criteria:  females with an age over 18 years; confirmed breast cancer (IDC, DCIS, ILC) with indication to undergo BCS;  a minimal tumor size of 1.0 cm (in at least one dimension):  IDC group: assessed preoperatively on ultrasound; DCIS subgroup: assessed preoperatively on mammogram; ILC subgroup: assessed preoperatively on ultrasound; NAT subgroup: assessed after NAT and before surgery on ultrasound; patients with IDC who have received NAT (i.e. chemotherapy, immunotherapy or endocrine therapy until eight weeks before BCS) may participate in the study; vacuum-assisted core breast biopsy is allowed in the DCIS subgroup only; able to understand treatment protocol and informed consent form; estimated by the investigator to be compliant for study participation.  Exclusion Criteria:  general or local contra-indication for BCS; previous breast surgery; inflammatory breast cancer; radiotherapy of the ipsilateral breast; vacuum-assisted core breast biopsy for all patients allocated to the IDC, ILC or NAT subgroup (vacuum-assisted core breast biopsy is allowed in the DCIS subgroup as long as the residual tumor size on mammogram is at least 1.0 cm); patients with DCIS only or ILC, and that have received NAT; blood glucose level over 200 mg/dL on the day of surgery; pregnancy or lactation; participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year; active bacterial, viral or fungal infection.